迈威生物: 迈威生物关于以集中竞价交易方式回购股份方案的公告

Core Viewpoint - The company plans to repurchase its shares through a centralized bidding process on the Shanghai Stock Exchange, with a total repurchase amount between RMB 25 million and RMB 50 million, aimed at employee stock ownership plans or equity incentives [1][2][5]. Summary by Sections Repurchase Plan Details - Total repurchase amount: RMB 25 million to RMB 50 million [1][5] - Source of funds: Company’s own funds and/or special loans for stock repurchase [1][12] - Maximum repurchase price: RMB 35.00 per share, not exceeding 150% of the average trading price over the last 30 trading days prior to the board's decision [2][12] - Repurchase method: Centralized bidding on the Shanghai Stock Exchange [1][6] - Repurchase period: Within 12 months from the board's approval [2][6] Purpose and Justification - The repurchase aims to enhance investor confidence, improve shareholder returns, and establish a long-term incentive mechanism for employees [5][12]. - The company believes its stock is undervalued based on its operational performance and future growth potential [8][12]. Shareholder and Management Actions - Major shareholders and management have no plans to reduce their holdings in the next 3 to 6 months [2][14]. - The proposal for the repurchase was initiated by the chairman and CEO, reflecting confidence in the company's future [15]. Financial Impact - The repurchase will not significantly impact the company's operations, finances, or future development, as the funds are manageable within the company's financial structure [13][16]. - The expected number of shares to be repurchased ranges from approximately 71,430 to 142,860 shares, representing 0.18% to 0.36% of the total share capital [5][7]. Regulatory Compliance - The repurchase plan complies with relevant regulations and does not require shareholder approval as it was passed by the board [5][6]. - The company will adjust the repurchase terms if there are changes in regulations during the repurchase period [7][12].